<SEC-DOCUMENT>0001140361-21-019853.txt : 20210604
<SEC-HEADER>0001140361-21-019853.hdr.sgml : 20210604
<ACCEPTANCE-DATETIME>20210604135252
ACCESSION NUMBER:		0001140361-21-019853
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20210604
FILED AS OF DATE:		20210604
DATE AS OF CHANGE:		20210604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nanobiotix S.A.
		CENTRAL INDEX KEY:			0001760854
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39777
		FILM NUMBER:		21995879

	BUSINESS ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
		BUSINESS PHONE:		33140260470

	MAIL ADDRESS:	
		STREET 1:		60 RUE DE WATTIGNIES
		CITY:			PARIS
		STATE:			I0
		ZIP:			75012
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc10025498_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Report of Foreign Private Issuer</div>
      <div style="text-align: center; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
      <div style="text-align: center; font-weight: bold;">of the Securities Exchange Act of 1934</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Date of Report: June 4, 2021</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39777</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">Nanobiotix S.A.</div>
      <div style="text-align: center; font-weight: bold;">(Exact Name of Registrant as Specified in its Charter)</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">60 Rue de Wattignies</div>
      <div style="text-align: center; font-weight: bold;">75012 Paris, France</div>
      <div style="text-align: center; font-weight: bold;">(Address of principal executive office)</div>
      <div>&#160;</div>
      <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
      <div>&#160;</div>
      <div style="text-align: center;">Form 20-F &#9746; Form 40-F &#9744;</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;<br>
        <br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter"></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div style="font-weight: bold;"><u>EXHIBIT INDEX</u></div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zfeb54650142c47ce9a7b315a5438d1d7">

          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibit</div>
            </td>
            <td nowrap="nowrap" style="width: 92%; vertical-align: bottom;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Title</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: middle;">&#160;</td>
            <td style="width: 92%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td nowrap="nowrap" style="width: 8%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);"><a href="brhc10025498_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 92%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Press Release, dated June 3, 2021</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageFooter"></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">NANOBIOTIX S.A.</div>
              <div style="color: rgb(0, 0, 0);">(Registrant)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="width: 47%; vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">June 4, 2021</div>
            </td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Philippe Mauberna</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Philippe Mauberna</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10025498_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: Arial;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="font-family: Arial;"> </font>
  <div>
    <div style="text-align: center; font-family: Arial; font-style: italic; font-weight: bold;"><a name="z_Hlk65001985"></a></div>
    <div style="text-align: right; font-family: Arial; font-style: normal; font-weight: bold;"> Exhibit 99.1<br>
    </div>
    <div style="text-align: right; font-family: Arial; font-style: normal; font-weight: bold;"> <br>
    </div>
    <div style="text-align: right; font-family: Arial; font-style: normal; font-weight: bold;">
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z1d394e5d345642c9886afec6a28097a8">

          <tr>
            <td style="background-color: #E7ED6D; width: 100%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 100.00%;">
              <div style="text-align: right; font-family: Arial; font-style: normal; font-weight: bold;"> <img src="image00003.jpg"></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: right; font-family: Arial; font-style: normal; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-family: Arial; font-style: italic; font-weight: bold;">PRESS RELEASE</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: center; font-family: Arial; font-weight: bold;">NANOBIOTIX REPORTS NEW DATA FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 IN COMBINATION WITH ANTI-PD-1 SHOWING LOCAL OR DISTANT TUMOR REGRESSION IN 76.9% OF EVALUABLE PATIENTS
      REGARDLESS OF PRIOR ANTI-PD-1 EXPOSURE</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: center; font-family: Arial; font-style: italic; font-weight: bold;">Data to be Presented at the 2021 Annual Meeting of the American Society for Clinical Oncology</div>
    <div style="font-family: Arial;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf3952da5d4c64d7aa16772a64eaa9545">

        <tr>
          <td style="width: 18pt; font-family: Arial;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: Arial;">
            <div>Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into responders</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z48edce5a75204cf68320e0ecd4724985">

        <tr>
          <td style="width: 18pt; font-family: Arial;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: Arial;">
            <div>Objective response was observed in 60% of anti-PD-1 na&#239;ve patients and 50% of prior non-responders</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8a9ce76221e245648df95a1f974147b5">

        <tr>
          <td style="width: 18pt; font-family: Arial;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: Arial;">
            <div>Data suggest abscopal effect in some patients (i.e., reduction in non-injected / non-irradiated lesions)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z38599b19f11e4546873d8c8cf2431aa8">

        <tr>
          <td style="width: 18pt; font-family: Arial;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: Arial;">
            <div>To date, the overall adverse event profile for the 16 injected patients has not differed from what is expected with radiotherapy or anti-PD-1 agents (head and neck cancer and non-small cell lung cancer primary tumors)</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z21d600a8d9ac433681fc7524fd9e4fe1">

        <tr>
          <td style="width: 18pt; font-family: Arial;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: Arial;">
            <div>New readout could provide promising signals for NBTXR3 as a potential pillar of immunotherapy</div>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z24ed6bd626264fe1b4ea5fb67c49556a">

        <tr>
          <td style="width: 18pt; font-family: Arial;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top; font-family: Arial;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: Arial;">
            <div>Following ASCO, Nanobiotix will host an investor event on Friday, June 11, 2021 at 8:00 am Eastern Time (14:00 Central European Time), to provide an in-depth review of the immunotherapy data with several key opinion leaders including study
              investigators (Register <u>here</u>)</div>
          </td>
        </tr>

    </table>
    <div style="color: rgb(255, 0, 0); font-family: Arial; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif;"><font style="font-family: Arial; font-weight: bold;">Paris, France; Cambridge, Massachusetts (USA); June 3, 2021</font><font style="font-family: Arial;"> - <u>NANOBIOTIX</u>
        (Euronext : NANO &#8211;&#8211; NASDAQ: NBTX &#8211; the &#8216;&#8216;<font style="font-weight: bold;">Company</font>&#8217;&#8217;), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced
        the upcoming presentation of updated data from the Company&#8217;s immunotherapy development pathway at the 2021 Annual Meeting of the American Society for Clinical Oncology (ASCO).</font></div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">Cancer immunotherapies such as anti-PD-1 have shown promising clinical outcomes over the past two decades and are often used to treat advanced cancers once other therapies have reached the end of
      their effectiveness. However, across tumor indications, the significant majority of patients (80-85% according to published data) receive only a temporary benefit&#8212;or no benefit at all&#8212;from anti-PD-1, as they either develop resistance to the therapy
      over time or are non-responsive to treatment altogether.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">&#8220;Improving response rates to immune checkpoint inhibitors is currently a key challenge for the medical and scientific community,&#8221; said Tanguy Seiwert, MD, director of the head and neck oncology
      disease group at Johns Hopkins Medicine. &#8220;The data we have seen to date suggest that NBTXR3 could bring a completely different local and systemic approach to overcoming this barrier in immunotherapy.&#8221;</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">Given early data showing immune activity triggered by the physical mechanism of action of radiotherapy-activated NBTXR3, Nanobiotix aims to address the significant unmet need in cancer immunotherapy
      by combining NBTXR3 plus radiotherapy with anti-PD-1 in advanced cancers to potentially improve treatment outcomes for patients regardless of their prior exposure to immune checkpoint inhibitors.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">&#8220;Changing the practice of immunotherapy is a challenge requiring innovation that can address unmet needs in the first-line for patients with primary resistance and in later lines for secondary
      resistance,&#8221; said Laurent Levy, co-founder and chief executive officer of Nanobiotix. &#8220;While our overall strategy is to develop NBTXR3 as a solid tumor-agnostic, therapeutic combination-agnostic agent, this particular study is designed to address
      both challenges by evaluating NBTXR3 plus radiotherapy in combination with anti-PD-1 across advanced cancer indications for both anti-PD-1 na&#239;ve patients and prior non-responders. The update we will present at ASCO adds to our growing body of data
      regarding our radioenhancer as a potential primer of immune response that could combine with anti-PD-1 and other checkpoint inhibitors to improve treatment outcomes for millions of patients.&#8221;</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial; font-weight: bold;"><u>Priming Immune Response and Immunotherapy Combination in Advanced Cancers</u></div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial; font-style: italic;">Abstract #2590: A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" id="DSPFPageHeader">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z1d394e5d345642c9886afec6a28097a8">

            <tr>
              <td style="background-color: #E7ED6D; width: 100%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: right; font-family: Arial; font-style: normal; font-weight: bold;"> <img src="image00003.jpg"></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="text-align: justify; font-family: Arial; font-weight: bold;">Background</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">The Nanobiotix phase I study of NBTXR3 activated by radiotherapy for patients with advanced cancers treated with an anti-PD-1 therapy (Study 1100), is a multicenter, open-label, non-randomized phase
      I dose escalation with dose expansion study to establish the recommended phase II dose (RP2D) of NBTXR3 plus radiotherapy in combination with anti-PD-1 in three (3) cohorts: (i) inoperable locoregional recurrent or recurrent and metastatic head and
      neck cancer (R/M head and neck squamous cell carcinoma; R/M HNSCC); (ii) lung metastasis; (iii) liver metastasis. The study is being administered in the United States.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">The secondary endpoints are objective response rate (ORR), safety and feasibility, and body kinetic profile.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial; font-weight: bold;">Updated Results</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial; font-style: italic;"><u>Safety</u></div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">NBTXR3 administration by intratumoral injection was feasible and well-tolerated. To date, the overall adverse event (AE) profile has not differed from what is expected with radiotherapy or anti-PD-1
      agents. 16 serious AEs were observed, of which four (4) were identified as NBTXR3 or injection related.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial; font-style: italic;"><u>Efficacy</u></div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">As of the data cut-off, 16 patients in the study received NBTXR3 plus radiotherapy and 13 were evaluable for response. Tumor regression was observed in 76.9% (10/13) of evaluable patients,
      regardless of prior anti-PD-1 exposure. The study reported tumor regression in 80% (4/5) of anti-PD-1 na&#239;ve patients and 60% (3/5) had investigator-assessed objective response, including one (1) complete response according to response evaluation
      criteria outlined in RECIST 1.1. In patients with prior primary or secondary resistance to anti-PD-1, 75% (6/8) had tumor regression and 50% (4/8) had investigator-assessed objective response. These included one (1) complete response and two (2)
      partial responses by RECIST 1.1, along with one (1) additional investigator-assessed pathological complete response. Some patients in the study showed delayed tumor response and/or abscopal effect, suggesting NBTXR3 may potentially prime an immune
      response.</div>
    <div style="text-align: justify; font-family: Arial;"> <br>
    </div>
    <div style="text-align: justify; font-family: Arial;">
      <table cellspacing="0" cellpadding="0" border="0" id="z624dfdd40e674f32ae3e55a3c01e9339" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50.00%;">
              <div style="font-weight: bold; text-align: center; font-family: Arial;"><u>Spider Plot &#8211; anti-PD-1 Na&#239;ve Patients</u><br>
              </div>
              <div> <br>
              </div>
              <div style="text-align: center;"> <img src="image00005.jpg"></div>
            </td>
            <td style="width: 50%; text-align: left; vertical-align: top;">
              <div style="font-weight: bold; text-align: center; font-family: Arial;"> <u>Spider Plot &#8211; anti-PD-1 Refractory Patients</u></div>
              <div style="text-align: center;"><br>
                <img src="image00006.jpg"></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; font-family: Arial;">
      <div> <br>
      </div>
      <div>&#8220;These updated data support the potential for NBTXR3 plus radiotherapy in combination with anti-PD-1 to yield a sustained immune response in both anti-PD-1 na&#239;ve patients and patients that have progressed on prior anti-PD-1 therapy,&#8221; concluded
        Colette Shen, MD, PhD, an assistant professor of radiation oncology at the University of North Carolina Lineberger Comprehensive Cancer Center and Study 1100 presenting investigator at ASCO. &#8220;NBTXR3 plus radiotherapy could stimulate immune
        response, convert anti-PD-1 non-responders into responders, and could be a promising next step for patients who develop immune checkpoint inhibitor resistance.&#8221;</div>
      <div> <br>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" id="DSPFPageHeader">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z1d394e5d345642c9886afec6a28097a8">

            <tr>
              <td style="background-color: #E7ED6D; width: 100%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: right; font-family: Arial; font-style: normal; font-weight: bold;"> <img src="image00003.jpg"></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="text-align: center; font-family: Arial; font-weight: bold;"><u>Swimmer Plot &#8211; anti-PD-1 Refractory Patients Follow-up</u></div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: center; font-family: Arial;"><img src="image00004.jpg"></div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="font-family: Arial; font-weight: bold;"><u>Nanobiotix Investor Event</u></div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="font-family: Arial;">Nanobiotix will host a virtual investor event featuring several key opinion leaders, including study investigators, after the ASCO Annual Meeting on Friday, June 11, 2021 at 8:00 am Eastern Time (14:00 Central European
      Time). The discussion will focus on the new immunotherapy data from Study 1100. Register <u>here</u>.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: center; font-family: Arial;">***</div>
    <br>
    <div style="text-align: justify; font-family: Arial; font-weight: bold;">About NBTXR3</div>
    <div style="text-align: justify; font-family: Arial;">NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by
      radiotherapy. The product candidate&#8217;s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term
      anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">NBTXR3 is being evaluated in locally advanced head and neck squamous cell carcinoma (HNSCC) as the primary development pathway. The company-sponsored phase I dose escalation and dose expansion study
      has produced favorable safety data and early signs of efficacy; and a phase III global registrational study is planned to launch in 2021. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for
      the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy&#8212;the same population being evaluated in the planned
      phase III study.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">Nanobiotix has also prioritized an Immuno-Oncology development program&#8212;beginning with a Company-sponsored phase I clinical study evaluating NBTXR3 activated by radiotherapy in combination with
      anti-PD-1 checkpoint inhibitors for patients with locoregional recurrent or recurrent/metastatic HNSCC and lung or liver metastases from any primary cancer eligible for anti-PD-1 therapy.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">Given the Company&#8217;s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a strategic collaboration strategy with world class partners to expand development
      of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to
      sponsor several phase I and phase II studies to evaluate NBTXR3 across tumor types and therapeutic combinations.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial; font-weight: bold;">About NANOBIOTIX:</div>
    <div style="text-align: justify; font-family: Arial;">Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by
      people committed to making a difference for humanity. The company&#8217;s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      <div style="width: 100%;" id="DSPFPageHeader">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z1d394e5d345642c9886afec6a28097a8">

            <tr>
              <td style="background-color: #E7ED6D; width: 100%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: right; font-family: Arial; font-style: normal; font-weight: bold;"> <img src="image00003.jpg"></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="text-align: justify; font-family: Arial;">
      <div>Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on the regulated market of Euronext in
        Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.</div>
    </div>
    <div style="text-align: justify; font-family: Arial;"> <br>
    </div>
    <div style="text-align: justify; font-family: Arial;">Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders
      of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate&#8211;NBTXR3&#8212;which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for
      the treatment of patients with soft tissue sarcoma under the brand name Hensify&#174;.</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; font-family: Arial;">For more information about Nanobiotix, visit us at<u> www.nanobiotix.com<font style="color: rgb(0, 0, 255);">&#160;</font></u>or follow us on <u>LinkedIn</u> and <u>Twitter</u></div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; margin-right: 14.15pt; font-family: Arial; font-weight: bold;">Disclaimer</div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; margin-right: 14.15pt; font-family: 'Times New Roman', Times, serif;"><font style="font-family: Arial; font-style: italic;">This press release contains certain &#8220;forward-looking&#8221; statements within the meaning of
        applicable securities laws, including the Private Securities Litigation Reform Act of 1995.&#160; Forward-looking statements may be identified by words such as &#8220;at this time,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;on track,&#8221; &#8220;plan,&#8221; &#8220;scheduled,&#8221;
        and &#8220;will,&#8221; or the negative of these and similar expressions. These forward-looking statements, which are based on our management&#8217;s current expectations and assumptions and on information currently available to management, include statements about
        the timing and progress of clinical trials, the timing of our presentation of data, the results of our preclinical and clinical studies and their potential implications,</font><font style="font-family: Arial;">&#160;</font><font style="font-family: Arial; font-style: italic;">the development and commercialization of NBTXR3, and the execution of the Company&#8217;s development and commercialization strategy. Such forward-looking statements are made in light of information currently available to us
        and based on assumptions that Nanobiotix considers to be reasonable.&#160; However, these forward-looking statements are subject to numerous risks and uncertainties, including with respect to the risk that subsequent studies and ongoing or future
        clinical trials may not generate favorable data notwithstanding positive preclinical or early clinical result and the risks associated with the evolving nature of the duration and severity of the COVID-19 pandemic and governmental and regulatory
        measures implemented in response to it. Furthermore, many other important factors, including those described in Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 7, 2021 under &#8220;Item 3.D. Risk Factors&#8221; and
        those set forth in the universal registration document of Nanobiotix filed with the French Financial Markets Authority (Autorit&#233; des march&#233;s financiers) under number D.21-0272 on April 7, 2021 (a copy of which is available on www.nanobiotix.com),
        as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the
        forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking
        statements, even if new information becomes available in the future.</font></div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="text-align: justify; margin-right: 14.15pt; font-family: Arial; font-weight: bold;">Contacts</div>
    <div style="text-align: justify; margin-right: 14.15pt; font-family: Arial; font-weight: bold;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z053787f04f9c4d93b83b4e9d9a076206">

        <tr>
          <td colspan="2" style="border-bottom: 2px dashed #000000; border-top: 2px dashed #000000; vertical-align: top; width: 69.58%; font-family: Arial;">
            <div style="text-align: center; margin-right: 14.4pt; font-style: italic;">Nanobiotix</div>
          </td>
          <td style="width: 30.35%; vertical-align: top; font-family: Arial;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="width: 69.58%; vertical-align: top; font-family: Arial;">&#160;</td>
          <td rowspan="1" style="width: 30.35%; vertical-align: top; font-family: Arial;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.08%; vertical-align: top;">
            <div style="margin-right: 14.4pt; font-family: Arial; font-weight: bold;">Nanobiotix Communications</div>
            <div style="margin-right: 14.4pt; font-family: Arial; font-style: italic;">Brandon Owens</div>
            <div style="margin-right: 14.4pt; font-family: Arial; font-style: italic;">VP, Communications</div>
            <div style="margin-right: 14.4pt; font-family: Arial;">+1 (617) 852-4835</div>
            <div style="margin-right: 14.4pt; font-family: Arial;"><u>contact@nanobiotix.com</u></div>
          </td>
          <td style="width: 34.57%; vertical-align: top;">
            <div style="margin-right: 14.4pt; font-family: Arial; font-weight: bold;">Nanobiotix Investor Relations</div>
            <div style="margin-right: 14.4pt; font-family: Arial; font-style: italic;">Kate McNeil</div>
            <div style="margin-right: 14.4pt; font-family: Arial; font-style: italic;">SVP, Investor Relations</div>
            <div style="margin-right: 14.4pt; font-family: Arial;">+1 (609) 678-7388</div>
            <div style="margin-right: 14.4pt; font-family: Arial;"><u>investors@nanobiotix.com</u></div>
          </td>
          <td style="width: 30.35%; vertical-align: top; font-family: Arial;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 35.08%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 34.57%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 30.35%; vertical-align: top; font-family: Arial;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="border-bottom: 2px dashed #000000; border-top: 2px dashed #000000; vertical-align: top; width: 69.58%; font-family: Arial;">
            <div style="text-align: center; margin-right: 14.4pt; font-style: italic;">Media Relations</div>
          </td>
          <td style="width: 30.35%; vertical-align: top; font-family: Arial;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="width: 69.58%; vertical-align: top; font-family: Arial;">&#160;</td>
          <td rowspan="1" style="width: 30.35%; vertical-align: top; font-family: Arial;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 35.08%; vertical-align: top;">
            <div style="margin-right: 14.4pt; font-family: Arial;">France &#8211; <font style="font-weight: bold;">Ulysse Communication</font></div>
            <div style="margin-right: 14.4pt; font-family: Arial;">Pierre-Louis Germain</div>
            <div style="margin-right: 14.4pt; font-family: 'Times New Roman', Times, serif;"><font style="font-family: Arial;">+ 33 (0) 6 64 79 97 51 </font><u><font style="font-family: Arial;"></font></u></div>
            <div style="margin-right: 14.4pt; font-family: 'Times New Roman', Times, serif;"><u><font style="font-family: Arial;">plgermain@ulysse-communication.com</font></u></div>
          </td>
          <td style="vertical-align: top; width: 34.57%;">
            <div style="margin-right: 14.4pt; font-family: Arial;">US &#8211; <font style="font-weight: bold;">Porter Novelli</font></div>
            <div style="margin-right: 14.4pt; font-family: Arial;">Stefanie Tuck</div>
            <div style="margin-right: 14.4pt; font-family: Arial;">+1 (917) 390-1394</div>
            <div style="margin-right: 14.4pt; font-family: Arial;"><u>Stefanie.tuck@porternovelli.com</u></div>
          </td>
          <td style="width: 30.35%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="font-family: Arial;">
      <table cellspacing="0" cellpadding="0" border="0" id="z2cc53de655dc473e9998b8e09a3aa824" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 25%;">
              <div style="text-align: justify; margin-right: 14.15pt; font-family: Arial;"><img src="image00001.jpg"></div>
            </td>
            <td style="width: 75%;">
              <div style="text-align: left; font-family: Arial;"><img src="image00002.jpg"></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="font-family: Arial;"><br>
    </div>
    <div style="font-family: Arial;">
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
  <font style="font-family: Arial;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !  '$# 2(  A$! Q$!_\0
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M!/<0[\F\D! +$?[1VY]!GUKM/CWKUYXBUW3/AMX:<F\OY%>_=3_JX_O!3[
MNWL%]:SOBEX*/PW'ASQEX+AV?V*L=M>QJ,>='T\Q\#^+)5C_ +0/:@#Z%4!5
M 4  #  [4M9?A?7+/Q)H%EJ^F2;[6ZC$B^JGNI]P<@^XK4H$%%%% !3)HUFA
MDB?.UU*G'H:?7FOQJU#7[&/PN/"MP8]0FU0*(BY5)P(W;RW]0=N/R^M '3^
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MT6YGFEC;2[P7D83&'8*RX.>WS'I6U10!P>L_"_0]3O?$ER6N+<Z];I%=+$0
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(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !/ %8# 2(  A$! Q$!_\0
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MR))&Z[61QD,#U!'<5#8Z?9Z?"8K"TM[6(G<4AC"*3ZX KY9_X:TG'_,HQ_\
M@>?_ (BC_AK6?_H48O\ P//_ ,10!]1W&EV%S=Q75Q8VLMU%CRYI(59TQR,,
M1D4D.DZ?!>/=P6%I%=29WS)"JNV>N6 R<U\O#]K2X)P/",9/_7^?_B*7_AK*
MYW;?^$/3=TQ]N.?_ $"@#ZIG@BN(7AN(DEB<;71U#*P]"#UJFNB:6MFUFNF6
M(M&;>T @386]2N,9]Z^8A^UC=$$CP>A"]<7QX^OR4X?M77A&1X,!'J+TG_VG
M0!]2VUM#:P)!;0QPPH,+'&H55'L!P*ACTNPCOFO8[&U6];[UP(5$A^K8S7S
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C(M*@TJZ$A"0PW0N0R8&&W #!Z\>U%;$./*3_ '1_*B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  W ,(# 2(  A$! Q$!_\0
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MMXD\)7WA^[EECM;N#[.[QXWA>.1GOQ0!X)\#M3L-(_9<UR\U>-9K)'NP\+'
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image00004.jpg
<TEXT>
begin 644 image00004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #> ;(# 2(  A$! Q$!_\0
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M_P * .LHKD_[<\4_]"?_ .5.+_"C^W/%/_0G_P#E3B_PH ZRBN3_ +<\4_\
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MQ,%62185!<+C;GZ8'Y5YO;Z'XJU.*!KN77+:6'?(9))XO-2X\E@WE$9Q"SX
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M4N=2=F[_  KN7&*:=V:G_"2_LZ_] ^P_\%\W_P 31_PDO[.O_0/L/_!?-_\
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MOVYZYK.=*$W>2N=F&S#$X6+C0FXIFD/#^A^&-!MXKV>5K6WO!=1F7YF:7H%
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MIZZ4BWUPT]NIM,(F0.) "-P!'&,5J>$=.NM(\-Z?IU_-!/<6L0A,D$91&"\
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M8?[%U3_H&WO_ 'X;_"M7PQHDW]M6[ZI97D5K&=[$V[G<1T'2OHG_ (:MT_\
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M_A7?C#_HJ6M_^ 4'^%'_  KOQA_T5+6__ *#_"O,/^&L[/\ Z%:?_P "Q_\
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MZ* "BBB@ HHHH X#_A&O$&DZRUYIE_%/IT4L]Q'8[2K3/*2V'.=IVLQPV,X
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M[_A5TZDJ4U.&Z(J4XU(N$]F=_P"(/V=?'VL:D]YY&B6[N!N5+QB"?7[E9O\
MPS%X_P#71_\ P+/_ ,36Q\$/%GCCX@^)I[+4/&FH6UK;P^<ZQ;/,DYQ@9''7
MDUF_%OQSX]\#>-+C1[7QG?7<"HLL;,$W*&_A;CJ*X9YM1K8Z6%E*]6W,]/Z1
M5.@J=-*/PK0A_P"&8O'_ *Z/_P"!9_\ B:T-"_9S\?:3J4=X8-$N&CR55KQ@
M ?7[E<%_PNOXA_\ 0T7O_CO^%'_"Z_B'_P!#1>_^._X5W4ZDJ<E..Z)G"-2+
MA+9GH7B3]GGQ_K>H?:VM]$MY"H5MEXQW8[_<K*_X9B\?^NC_ /@6?_B:Y+_A
M=?Q#_P"AHO?_ !W_  KW?P+#XS\2?#$^()_B#J$6H31O+"%V>3$%SP_')XY]
M*X<TS>EA%]8Q<OB=KVZOT*H4%&*ITUHCS7_AF+Q_ZZ/_ .!9_P#B:TO#_P"S
MKX^T?4DO/(T2X= =JO>, #Z_<K@3\:OB&"1_PE%[_P"._P"%)_PNOXA_]#1>
M_P#CO^%=U.I*E-3ANB:E.-2+A+9GH'B+]G?Q_K.HM>&WT2W=@ P2\8AB._W*
MS/\ AF+Q_P"NC_\ @6?_ (FG_"CQWX_\<>-+31I_&=[:0NK22. NXJO)5>.I
MK9^.7B?QQ\/?$%I;:=XUU"YM+N(RHDNPR1X."&P.0>Q^M<-?-J,\=]5J2_>R
M7-M_2*IT%3II07NK0P_^&8O'_KH__@6?_B:LZ;^S7X]LK^"Y>+19Q$P;RVNV
M ;'_  &N)_X77\0_^AHO?_'?\*/^%U_$/_H:+W_QW_"NR,G&2DMT*45).+ZG
MI/BCX!?$#Q!-#+):Z'!+&"I9;QCN'8?<K#_X9B\?^NC_ /@6?_B:QO"_Q5^(
M>N^(M.TH>+[NW^V3I!YKA<)N.,]*]/\ CIJ'C/X?:;IE]I?CC5)TN',,D5QL
MW%@,[EP.GM7)C<XI_7(4<1+]Y4VT[>F@4,-&E3Y::M%'$_\ #,7C_P!='_\
M L__ !-36?[,_CVWNHIGCT658V#%#=L V.WW:XS_ (77\0_^AHO?_'?\*/\
MA=?Q#_Z&B]_\=_PKK3<7=#:35F>F>*/@+\0/$ @,EIH4$D60'2]8Y'I]RL#_
M (9B\?\ KH__ (%G_P")KE8OC1\0WE13XHO<,P'\/^%==K?Q$\;V.DS7,/BO
M5#)& 0&*$=0/[M3B\<YU5*L[RD=V69'5KX>I/"I<E)7>OJ]/N9'_ ,,Q>/\
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M!!'BW5L]01!+_P#&ZMSZ+\%)X3%-XWUMXSU5H9L'_P A5]<QVEO'&D:0QA%
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M67AS2;+6=1U6UL8H]0U$1BZE R9!&,)QT& >U:J@*,*  .PH 6BBB@ HHHH
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MY 6R!MSLXQD'UQFI[/QW>W:QVT'A]O[8>0#[(]X@41F(2!_,QC.&'RXZY]*
M.\HKC?#'CF/7_$U_I4.FW<4-NTJ)=,C;':-]C@G: .0<88Y [5S%GX\UI;NW
MLKYK87%S=W;6[K'@2VR13$ #/WD=%#>Q'3- 'K-%>+Z?XJ\5WOA2ZNGU7['>
MV_V28"XTZ,/)'.54_('(V@DE3G)QR*Z.\\1:UIOB&71)+ZTN&AM#>->-#L+%
M8F)@VC@.2OF=?N9XZ&@#2E\'/+\1(O$):TC@B4L%CC(ED<IM^8YQ@#OC/:NS
MKR3PWXD\5:MX/O;AKBZ.HQ?9Y$6'3HC<8DCW$&(OMV$D%6W9(SQ737'BJ>+1
M?#&HK);S17T;37!B!*R*MN\IV9P1DKWH [6BO.K7XA23VVGW-]IT^FB2>/?$
MKI/NADMI)E)(Q@X3D#G..QI=%^)$VL6L L] N?[0N)_*A@FD,2.OEF0MYCH.
M@!R #SCF@#T2BO.D\>7D+SSZSIWV&UMKVYMS]GE6<RK%$SG(P"I^7MUJPWCO
M4586;>'&_MCS5C^RB]0IM:,R!O-QCHI&,=<>M '>T53T>_CU32K2^A5DCN(E
MD56ZC(S@U<H @OK:.\LI[:9$>.5"C*XR#D=Q7G6D^ M6L$\(V4M[:3Z1HJ%I
M;?:R^;-N8J_N%!X4]^:],HH **** "BBB@ HHHH *YWX@>'?^$I\)W^DJT4<
MLZ@1R2+N",&!S^E=%10!R%EX7NXO&D>L236B6\,+QA8(BLDQ8*/WAS@[=IQ]
M:Z^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J*XMH+AHC/#'(8GWQEU!V-ZCT-2T4 9C>'](:Q-D=,LOLAB\@
MP^2NSR\YVXQC&3G'K26_A[1[:!(;?2[*.)(O(5%A4 1[MVWITW<X]>:U** ,
MZ/0M*CNIKF/3K1;B9S))((E#.Q7:6)QU*D@GTI+'0=)L+Y[RRTZTM[IT$331
MQ!6*  !<CL !Q[5I44 8]KX8T.TC,=MI%A$A=I"JP*!N92K'IU*D@^QQ3M0\
M-Z+J,+0WVE65Q$S*Y62%6!95VJ>G4#@>U:U% &?:Z+IEIJ4^H6MA;0WTXQ+.
MD85W'N>_04-HNF,8"VGVA,!=HB8E_=EP0^WCC<"<^M:%% &/IOAC0M,LY;33
M](L+:UF97DBB@55<K@@D <XP,5:ETC3IO,\VQMG\R7SWW1@[I-NW<??'&?2K
MU% &1?>&=#O[<07ND6,\(5%"20*0 @PHQCH >/2KDNFV4L,,,MI \4*E8D,8
M(0%2I ';Y21]#5NB@#$NO#.GSW^F7**;==/D$J0PJJH["-HTW<9(568  @<]
M^*:/"'AT6#V7]B:=]D>03-#]G787'1L8Z^];M% &;'H.DQW4ERFFV:W$AW/(
M(5W,=NW)./[I(^E,TWP[HVEP1PZ=I=E:Q1NTB)%"JA6(P2,#J1Q6K10!';PQ
M6T"0V\:111C:B(,!1Z 5)110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '):IJ
M_BBT\8>1!HEK+X82T::2_-SB02 $[=GU 'XY[8K"T#XG)-X?FU;6K,):*T8$
M]B'DC&Y2Q4^8J'<N.< CYA@GFO1YXEG@DBD&4D4HPSC@C!KG]=\&:1K>BV6E
MWJ3_ &6S 6'RYF5@-I3!/?Y3CF@"A!X]L[J]DABMKJWABNHX#<W4++'*KQF0
M&,C.>!GG'%16GQ.\/7MHTUB;RZ<2I"L$$!DE<NI9"%'8A6P?8UJ)X-T=+DR^
M7.5W1.(6G8QAHT,:D+G&=IP?7C-,T7P3H^C^7]C2XVQ3">)7F+"-@I4 >V">
M* '>'_%]IKNKW%E96E_Y<5O'<"ZDAVPNKC( ;U]B.Q]*Q]!\9ZI<W-JVJ:7;
MK97PN#:-92M++F$ME70J.2%R-I//%=%I'AK3](O5N;#[1&1;K;&/SV,;*I)!
M*DX+#)&[K@XJEI?@C2M-FDEMY+\N5D6(R7;O]F$A)?RLGY,D]J )_$/BNQT*
M:TBNX+^66XB><);6S2F.-"H=WQ]T#>N?K61<>+M3:'6=2T_3[2?1=-6=6=K@
MK,[QQERP7;C83@=<]\5?\1>#X=>UG3KNZO+N.WM+6:V:*"9HVF\QHC\[ \KB
M,@J>N?:GW'@K2)[J\E(NDBNT=9K:.Y=(&+)L+^6#C=MXW=: ,OPSXUN=4\(Z
MKK,]O9M]B5F1K65S%* @8C+JK C.#E?3&:<OQ(TE- ;4[NVU" 1,B3PO;E7C
M+)O!P<94CD$=:Z'_ (1_3_)U"+RW\N^B6*X7S#\P5-@/L=N!GJ<#TK#F^&^@
M3Z;]CG%]*ID$C2R7;M*V$V!2Q.=H7C% $M[X_P!$LVU+SFN/+L3&KRB+Y':0
M HJ$GDG</;KZ52O?B1IAL+*XTF"ZOS<M#DI$=D DE$?[UAD*<[L#U'XU=NO
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MH3AGD6,W#F%'<8=A'G:"W<T 4+KQWI]C<307<=S+(D\L9^R6[R"-(]NYW..
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0&.*,82-0JC.> ,"B@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00005.jpg
<TEXT>
begin 644 image00005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #P 2H# 2(  A$! Q$!_\0
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M?1P]=(\,3R!WC5G *@D=CU%<3:R7.GZ]:3"UC59)I[)_WN.'<R1_P]F#J/\
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M^K;Z&L'X??\ (EZ1_P!<!_6MZ3_5M]#6#\/O^1+TC_K@/ZT =!1110 4444
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M6><V4C1R^6)K*0R0R#:K95CUQNVGW4UK:C,]MI]S/$J-)'$SJKN$4D D L>
M/>I8HHX8PD*+&@Z*HP!3F4,I5@"I&"",@T >5K\3;U;5));73A*JXFC\\\L6
M<;T(R&C39\S D<UZ!X8U*35M&BNYA!YA>1"UN^^)]KE=R'NIQD?6KXM;<!0(
M(@%4HN$'"GJ/I4L:+&BI&H5%& JC  H R?%NKOH7AV]U&*$3R0J"J,X1220
M68D  9R22.!7#+\2+M_LX6/2H_. B+33E1 ^ 3+)UQ"2=JL"<DKS@UZ>Z+(A
M1U#*PP01D$5$;2W8$&WA(*A#E!RHZ#Z4 5]"OGU+1K*]DB\EYXED9,YVDCM[
M5/?/)'93O T*RK&S*TQ(0$#JV.WK4X  P!@"@@$$$ @\$&@#S&;X@ZG:K$+N
MWTI)&1#@SNI*R%MD^",B(  L3R,UW7AG4I-6T.VO9EA$D@8$PMNC;#%=R$]5
M.,CV-:#00NV7BC8[=F2H/R^GT]J>BJBA4 55&  , "@!:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC?B?:376E6C6\%Y<
MR0S&1+>&)I(Y6V,%60*RLHR>'!^4X-=E10!Y;!/XFT:XU&00ZS<+)?3N\/E)
M,%#PYB\H@#*A^#SQ@9ZFJUTOBR\U.UGN3?07=FDDJ,T$8MH_]$X;=C.XN75A
MR!GH, GUN@C(P>E '!+JFO7W@>RU:,7L37]REQ(EM CW%M:.<J$4@AF V9R"
M<%CVKFM)/C2T?3M/M1>V-NEFP=Y[=&C#%)&$C'&$._8"N3U)P!7L73I1UZT
M<_X%U&]UGP]#JNH*T1OB;B&!E ,,1^XIQU.!G/OZ5T%     P!T%% !1110
M4444 %%%% !1110 4444 %%%% !1110 R241XSGGTIGVE/1J9>=5J @CJ,4
M6OM*>C4?:4]&JI4:3Q274ELDB-<1JKO&#EE4YP2/0X/Y4 7_ +2GHU'VE/1J
MJ@$G !S4=Q+';0&:X=8HE(!=S@#)P/U(H O?:4]&H^TIZ-5&&1)O,\IM_EN4
M?'\+#J*+B6.W5&N'6-7=8U+'&6)P /<F@"]]I3T:C[2GHU5<$=C5>]NH;*))
M+I]B/*D*G!.7=@JCCU)% &E]I3T:C[2GHU5=IYX/'7BC!]#0!:^TIZ-1]I3T
M:JNT^A_*@@@9(- %K[2GHU'VE/1JJ[6]#S[5!#<PS7$L$4BO-$<2(.J_6@#1
M^TIZ-1]I3T:JA! R>!ZTRWE2YMTGMW66%UW(Z'(8>H- %[[2GHU'VE/1JJX.
M,X.*AN+F&V=4N)5C=E9U5C@E5&6('L* -#[2GHU'VE/1JQ-4UK3-*MX9]3OH
M+6&8XB>5L!SC/'X<U'!X@T>XU4Z;!J=I)J ZP+)EONAOQ.T@X]#F@#?^TIZ-
M1]I3T:LMK^S744T]KJ$7SQF9;?>/,*#@MCTY%2M-$DT4+R*)9<^6A/+XY./I
M0!?^TIZ-1]I3T:JH4GH#^5&ULXP?RH M?:4]&H^TIZ-57!XX//2C:?0_E0!:
M^TIZ-1]I3T:JNUA_"?RHVGT/Y4 6OM*>C4?:4]&JB9$%P("W[XKO"=RN<9J3
M:>>#QUXH M?:4]&H^TIZ-57!]#1M;T/Y4 6OM*>C4?:4]&JI10!HJ<@'UYHI
ML?\ JU^@IU %>Z.&0US_ (9\/V7ANRN+73FNFBGN)+IS<3&5M[G)P3T'M6_>
M=5JO0 5R6O>%&UC7S=7!@DL'-OYL#E@76/S<@XX(.]>/8UUM<UK/BC^S]4FM
M$LGEA@,,=Q<>:JF)ILB/:A&7'3.",>^#0!C>(/#.HW6C>'--6WM=0-K'-%<?
M:)G2(9CVHQ(!)(."..H['!K)NOAUJEU>:A)>7%A>+-;"(&5F47#*8BGF($X(
M\MLMN8G=G Z5IZ7X\NETNS.H:86G:*":2X%ROE"*3</-<JIV<IC;@]1S5JW\
M>27:W#VGA^_>$3K;VLTC>5'<,93&?F9<+@C/&[C/?B@"EJ'@?4+S4[&Y>=?L
ML,SR"UAO&A$&75E9&\MLD %<87C'/--F^'S^0NV/3[F7S$GF2=GV3R+<&0%C
M@_\ +-BH.#Z=*O7_ ,08[1GMUTBZGOXY3;RVT3[S'+OVJA(4GY@"X('3''-)
M)XQO+K5M)M;73IK*-[RW@O#<LJR(TD32>5Y9&>FWYN/IUH GTSPM=Q:7XCLY
MC;0)J#F2V,<AED1SDAW<JI;#8(&#@#&36=%X'U&X1H]7N[:YA:6&?R][D%C,
MDMQGCH2F%]C@XK1U#QE)8WU] NG/=BUEF,CB58A'%&L)8\YW'][P.,X/2CQ9
MXP&C^(M&TR%X(UN)HA<//&YW)(2JK&1QNR"23T&..: ,]/!-_'=VFR2S,4#I
MY$YED$EBB3,^V)<8(9"JG)'3N,5<\3>%M5O]9N[S2KZ&WBD"R1QR,XVRLOE2
MDX[&+[OHXS[U>U?Q6]CJD]G#IS3I%*EJTQG5,3NA9%V8R5X +=L]#@UEKJWB
M1/ &B:K&/-N9HA=7\GEQS-%"8R^57=$I .!C.0/4\T 4?^%>7)N]5$EP98;I
MU"R27C?-")8V\MXP@Z(I4'>?H,FM?PWX2FTCQC?ZH\ADMY3((2MR0%C;;LB,
M.S&$ P#O. . ,U:U[Q<FEV]E+;V37T<]C)J#.)EAVPQB,L0&ZL1("%]NM8]Y
M\0+B6^EL](TI9)$N;=$FEF*Q3Q/<"%BI*## G'&0">O&* *]]X O#IDT%E)9
M^9<@?:Q([?OR)F<'<5;!"L &VG&,8QC$L?@C6!86D1U.+SE2.VN',CL&MS$$
MF X^\=JE3]>F:N6OCIWU""R32;Z\D+2&XF@C.VW03R1*3@$$?NR221QSUXIL
M7C74;NYTN*UT5(FNIX=RS7:DF"6.1E8$#ALQGC]>> ";PCX0FT?5-7GOI6N5
MO!(GF&Y+B1&<E0T6P8*J=H.]N 0, UDV/@._MH=-A2+2X%MDB1)H9I UJ4D+
M,\2[0"9!@,"1CU85O?\ "9(GA>]U>XT^:.:UF6W:P5B\PD9E5$<;?E8EEXP<
M Y&:JGQ\D*JFHZ3=:?=O'YJP73^62@+^8_*Y"H(]Q)&2&'% %?Q-X/U35?&$
M^J6US;0V[V[0(1(R.%:)D*D*N3\QW;MW  &,C-13> 6BNHI+&'3]D1E$(=G!
M@\R!4+H<'YMZ[L<9R3G-+:^/Y+B:WGDL)[6)6>">TD/S;S)"JON90<8ES@@5
M=NO'T$>J6]E%8R2K+<O:/,DF[R&$KQ*S +C:S(<98'KP<4 3:EX1GO\ ^S%E
MUB_$4);SPLP!"F(H5C.SA3GG/..]4T\(7XO)+.)K2UT5=3348)8I&:XC"0I&
ML:J5PIROWMQX[<UG6?CZZ33-'EU*$PN(HKJZ>-DE^TPM!,V0 /D;=%]W]>M;
M%UXGU.\\"ZEJ=GI-SIU_'M2&.Z.S(8J!(I9.<;NZXR.] %F]TO5+7Q!IFH6L
M<5_;6-K/'))//_I4[.!@8$>TXVX&2/O=L<GB/P]-KTVC7KVMI'=013)()F):
M#S8\91@.2K?3/J*HGQP]G; 3:7//\DBP2?:8R]Q)$ZHX8  )\S<'H<=!TK0U
M_P 1:CI%_9+)IL+VQL+B\NU%R-\;1!3M3Y?FZX[9SVQ0!A2>"-4U.#;K4EB=
MMOY21Q32,H=;?RD<D@<[OGZ<<=2,TVZ\!7:0O!:BQGLR/EM;B:14CD:%$:<$
M DN'5F'KN)R#6KJWCE;.26.TTN2\>%7DDVW"(%1($F8\CKMD  [D=@:8_CF5
M5DC_ +%<7D,<EQ/ UV@"0(J,6#XPS8D7Y>._/&: +5KX5DM]$\00"9)-3U..
M2/[8S-N8&,*NX]1@Y.!TR:Y_4O MY:ZE<7VE[VBBLO+M(8+LPF%A"RE FP[P
MS$MRZ\MD@XKI[7Q29]%UC5?[.E6SL#(L?[Y2]QLZX7'R>V35 >-KLZC<62^&
M=2GFMH=T_P!F/FJDIC\Q8PVT*<@J,Y')Q@]: .9\(>"+NXTEVN[1M*NDCN4B
M=_E99Y$C5)T0 !=NTCUSDCK5_3? E_91Z8(4MUDMYVDD\Z_:9%5@H;RU\E0K
M':<,,%2<_-DBM5?'L9\M_P"SP]NHB-S+%=!O),CM& %*AG(92",#'N12Q^.)
MY?LT<6ANUU>&%K6(7J8>.59&5F;'R'$1RN#UX)H S;7P3JT6DI:M)8>5'P+0
M2MLFC\U6\N5P@W$@$,^W)XR#S4]CX&N898+B26V6X@>![94DD*VJK<-(\:$_
MP[&V XYZ$ 5-)\0X8[5KAM+N CV\4ULA?]Y<LY5<(H4Y4,X!8$X/;D5U>AW\
MNIZ5!=W%C<6$L@.ZVN%(="#CN <=P<#CM0!S'B;PMJU]K-Q>:3J$5O&ZK(B2
M,WR3%?+=L 8P8R?^!8Z=:PYOA]J?VS671K-X+J-8X8_M+1JVV0-&77RB/E4
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MD@#(\PDCIT'% &_1110 4444 7X_]6OT%.IL?^K7Z"G4 5KSJM5ZL7G5:KT
M%<;XM\0ZSI4^J/86]I+:V4$! D1MQ>5B"Y;< $0#)]?4=:[*E!(Z$T >9R>.
M]5MX=]RNE/)_9[W2I:,9PSJ6RS%6^1,!<8#9)(SD<MD\=ZHL+F.33)45I/L]
MT+>7R]09=F(8ANRK_,1G+<C@=<>E7,275O)!<HLL,@PZ.,JP]Q4FXCH3Z=:
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%%.H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image00006.jpg
<TEXT>
begin 644 image00006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" #P 3\# 2(  A$! Q$!_\0
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M:K)<FV%L$/G7"R!VPFW"C[K##[C_ !;AUJQX)@=] )%S,@-Y><*%X_TF7U%
M'3U4U#;OL]W_ #W&/KM:G&VD)S]LN![83_XFJM];2[K8"\N.9@,X3CY3_LT
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M;S*5)O)FP<D%4Y]ONTAF3X-_X\]1_P"PC=?^C36_7/\ @D;--O(QC]W?W*Y
MP6_>MR??WKH* $90WWA4<5O'&,*#USR:2YBDE"^5<208ZE%4Y_,&LO1M#ETN
M%XTU2[E5Y6E/F!3U/3D9KGJ4XNHI.%_/0TC"+BVY6?;4ETO1+?3=5U.^MY)2
M^H.LDJ,$P&  R"%#=!T)(';%:M<MI_AV\M/&EUJQN;9[297ROD_OB3MPI?\
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MP_R,^5K1E)I+]Y(@D$4:[QYA9]WR]\8[U=HHJHQMUN"044450PHHHH ****
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MB:ZO#>7%S9W$,D@\RU>$(WF !3E !C!Q@DD'G&.?0=6-P--N39,%N0A,;'&
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MR&4C!!'I6/H?AFPT*\FFTLSPPRQK&;;S2T2A?N[0<[<9(P#CGI6W10 4444
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M$CQOF1BJ$83;NR2^ ,9R/>@^--(+1B'4%E#!&9E4A45@2"21C.%/R_>X/'%
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M'!0$<9QGWJO:^'_$MI(90\\EW-=6UQ.XU$K%+B!(Y R@@@!E9OE^]\H((&*
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M'4(NU<''&!QD>E:]<UX'L-:L+&Y7Q#=W%U=/(&#2R*Z].2F.0I/.T]/05TM
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M*56;9T) ;CG!QSTI=8\"6VJWUG/>3)+Y5M#;3&2(EYA'(''S;A@$@YX/;GU
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)('/0#)ZT ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
